5 Key Takeaways
-
1
Optegra is offering Espansione’s eye-light photobiomodulation treatment for dry AMD at five UK hospitals in London, Manchester, Colchester, Bradford, and Hampshire.
-
2
The treatment delivers yellow light at approximately 590 nm and red light at approximately 630 nm through closed eyelids, treating both eyes in sessions of about 12 minutes.
-
3
Optegra’s protocol includes eight sessions over four weeks, with some patients potentially receiving another six-session cycle about four to six months later.
-
4
A cited study found that more than 20% of treated patients gained at least five visual acuity letters after four months, and treated eyes had a significant reduction in mean drusen volume versus sham.
-
5
Patients aged 50 years or older with confirmed dry AMD may be assessed for suitability; further research is needed to establish treatment durability and identify likely responders.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
